Thought Leadership
Journal Article
Combination-product growth has surged globally as both physicians and patients request fewer invasive procedures in favor of user-friendly treatment delivery options.
Journal Article
Advances in the cancer treatment space have renewed hope for breakthroughs with personalized cancer vaccines (often also called personalized immunotherapies). More recently, there have been promising results in a number of areas, including pancreatic cancer, melanoma, and non-small cell lung cancer (NSCLC).{1} According to analysts, significant growth is expected for cancer vaccines, with one report noting that the global market for cancer vaccines should grow from $10.21 billion in 2023 to $30.16 billion by the end of 2033.{2}
Blog & Article
- 13th September 2024
Infographic
Regulatory requirements for combination products vary significantly by region, and registration frequently necessitates a dual assessment approach. We can manage the intricacies of borderline products and navigate unique regulatory pathways in all major markets.
